scholarly journals Type 2 Diabetes Mellitus and Cancer: The Role of Pharmacotherapy

2016 ◽  
Vol 34 (35) ◽  
pp. 4261-4269 ◽  
Author(s):  
Gadi Shlomai ◽  
Brian Neel ◽  
Derek LeRoith ◽  
Emily Jane Gallagher

Purpose Type 2 diabetes mellitus (T2DM) is becoming increasingly prevalent worldwide. Epidemiologic data suggest that T2DM is associated with an increased incidence and mortality from many cancers. The purpose of this review is to discuss the links between diabetes and cancer, the effects of various antidiabetic medications on cancer incidence and mortality, and the effects of anticancer therapies on diabetes. Design This study is a review of preclinical and clinical data regarding the effects of antidiabetic medications on cancer incidence and mortality and the effects of anticancer therapies on glucose homeostasis. Results T2DM is associated with an increased risk and greater mortality from many cancer types. Metformin use has been associated with a decrease in cancer incidence and mortality, and there are many ongoing randomized trials investigating the effects of metformin on cancer-related outcomes. However, data regarding the association of other antidiabetes medications with cancer incidence and mortality are conflicting. Glucocorticoids, hormone-based therapies, inhibitors that target the phosphatidylinositol 3-kinase-Akt-mammalian target of rapamycin pathway, and insulin-like growth factor 1 receptor–targeted therapy have been associated with high rates of hyperglycemia. These agents mediate their deleterious metabolic effects by reducing insulin secretion and increasing insulin resistance in peripheral tissues. Conclusion Studies must be performed to optimize cancer screening strategies in individuals with T2DM. A greater understanding of the mechanisms that link diabetes and cancer are needed to identify targets for therapy in individuals with diabetes who develop cancer. Data from clinical studies are needed to further elucidate the effects of antidiabetic medications on cancer incidence and progression. As several anticancer therapies alter glucose homeostasis, physicians need to be aware of these potential effects. Careful patient screening and monitoring during treatment with these agents is necessary.

Author(s):  
Francesca Farrugia ◽  
Alexia Aquilina ◽  
Josanne Vassallo ◽  
Nikolai Paul Pace

Type 2 diabetes mellitus (T2DM) is characterised by insulin resistance and eventual pancreatic β-cell dysfunction, resulting in persistent high blood glucose levels. Endocrine disrupting chemicals (EDCs) such as bisphenol A (BPA) are currently under scrutiny as they are implicated in the development of metabolic diseases, including T2DM. BPA is a pervasive EDC, being the main constituent of polycarbonate plastics. It can enter the human body by ingestion, through the skin, and cross from mother to offspring via the placenta or breast milk. BPA is a xenoestrogen that alters various aspects of beta cell metabolism via the modulation of oestrogen receptor signalling. In vivo and in vitro models reveal that varying concentrations of BPA disrupt glucose homeostasis and pancreatic β-cell function by altering gene expression and mitochondrial morphology. BPA also plays a role in the development of insulin resistance and has been linked to long-term adverse metabolic effects following foetal and perinatal exposure. Several epidemiological studies reveal a significant association between BPA and the development of insulin resistance and impaired glucose homeostasis, although conflicting findings driven by multiple confounding factors have been reported. In this review, the main findings of epidemiological and functional studies are summarised and compared, and their respective strengths and limitations are discussed. Further research is essential for understanding the exact mechanism of BPA action in various tissues and the extent of its effects on humans at environmentally relevant doses.


2020 ◽  
Vol 11 (4) ◽  
pp. 383-387
Author(s):  
Yuji Iida ◽  
Soichi Takeishi ◽  
Nobutoshi Fushimi ◽  
Kazuhiko Tanaka ◽  
Akihiro Mori ◽  
...  

2018 ◽  
Vol 54 ◽  
pp. 104-111 ◽  
Author(s):  
Roy G.P.J. de Jong ◽  
Paul J.H.L. Peeters ◽  
Andrea M. Burden ◽  
Marie L. de Bruin ◽  
Harm R. Haak ◽  
...  

Author(s):  
Raicha Namba ◽  
Eugène Sobngwi ◽  
Andréa Omengue ◽  
Armand Mbanya ◽  
Jean-Claude Njabou Katte ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document